LONA LeonaBio, Inc.
Financings ·
LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised.
LeonaBio said it enrolled the 500th subject in its ELAINE-3 trial of lasofoxifene, an announcement that also sets a date used in the exercise terms of its Series A warrants.
LeonaBio reported cash, cash equivalents and investments of $51.1 million at June 30, 2026, and said it has enrolled 495 patients in its Phase 3 ELAINE-3 trial.
LeonaBio said it is increasing the ELAINE-3 sample size to up to 600 participants and expects to start a Phase 2 ALS study for ATH-1105 in the second half of 2026.
The transfer takes effect April 17, 2025. Athira, now LeonaBio, has until October 13, 2025 to lift its stock to $1.00 and is seeking approval for a reverse split.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $17.5 million | $70.7 million |
| Net income (loss) | -$105.6 million | -$96.9 million |
| Cash from operations | -$45.7 million | -$97.2 million |
| Cash and equivalents | $69.3 million | $48.4 million |
| Short-term investments | $19.1 million | $2.8 million |
Our latest story on this, dated Apr 16, 2025: "Athira Pharma (now LeonaBio) wins Nasdaq Capital Market move and 180 more days". The story links the filing or release it is based on. Read the story.
LeonaBio, Inc. trades under the ticker LONA on NASDAQ.
LeonaBio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for LeonaBio, Inc. is 1620463. Its filings are on SEC EDGAR.
9,421,663 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-14.
Our directory records LeonaBio, Inc. under United States.
Our directory classifies LeonaBio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for LeonaBio, Inc. is US04746L2034.
aibio.space lists LeonaBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
LeonaBio, Inc. reported a net loss of $105.6 million for the fiscal year ended Dec 31, 2025, and used $45.7 million of cash in operations, per its annual report to the SEC.
$17.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$51.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on LeonaBio, dated Sep 22, 2026: "LeonaBio Series A warrants become exercisable at $6.35 a share". LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised. Source.
Our latest financing story, dated Sep 22, 2026: "LeonaBio Series A warrants become exercisable at $6.35 a share". LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised. Source.
We do not publish live share prices. In its annual report, LeonaBio, Inc. put the market value of shares held by non-affiliates (public float) at $9.9 million as of Jun 30, 2025.
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a financing. SEC Form 8-K (Items 5.02,5.03,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio